Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a poster at the upcoming 2026 Tandem ...

Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological malignancies, today announced that it has received ...

Lenora “Nook” Hamer Flakes was a lifelong resident of Ruleville, Mississippi. According to Mississippi Today, she worked as ...

Deer Valley Resort will host its annual Shred For Red fundraising event on March 28, welcoming spring skiers to a day of ...

Many people's worst nightmare is being diagnosed with a terminal illness. It happens when you least expect it, and suddenly, ...

CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved for the treatment of patients with multiple myeloma who have had at least one prior line of therapy. Globally, CARVYKTI ® is ...

Norton Children’s officially opened the Cancer Institute Resource Center inside the Novak Center for Children’s Health, ...

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer ...

When lung cancer treatment stops working, what happens next? New research reveals the answer may depend on how the cancer grows.